ArticleInternational journal of clinical and experimental medicine2015
Association between the CD28 IVS3 +17T>C (rs3116496) polymorphism and cancer susceptibility: a meta-analysis involving 8,843 subjects.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 7 citations in OpenAlex.
- Investigation ofBioscience reports · 2019Pooled it
- Association Between the CD28 c.17 +3 T>C Polymorphism (rs3116496) and Cancer Risk: An Updated Meta-Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2019Pooled it
- Relationship betweenCancer management and research · 2018Article
- The association betweenBioscience reports · 2017Article
- Article
- The relationship betweenOncoTargets and therapy · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The possible association between CD28 IVS3 +17T>C (rs3116496) polymorphism and cancer susceptibility has been widely investigated. However, the results are conflicting. To verify the association more precisely, we performed a meta-analysis of 11 publications involving a total of 8,843 subjects. In this meta-analysis, 11 publications were included by searching PubMed and EMBASE databases up to May 23, 2014. The cancer susceptibility associated with the CD28 IVS3 +17T>C polymorphism was evaluated by odds ratios (ORs) with 95% confidence intervals (95% CIs). Heterogeneity, sensitivity and publication bias analyses were also assessed. The result suggested that the CD28 IVS3 +17T>C polymorphism is not associated with cancer susceptibility in overall cancer. In a stratified analysis by ethnicity, the association of CD28 IVS3 +17T>C polymorphism with cancer susceptibility was significant in Asians. In a stratified analysis by the origin of cancer cells and system of cancer, CD28 IVS3 +17T>C polymorphism was not associated with cancer susceptibility. In summary, this meta-analysis demonstrated that the CD28 IVS3 +17T>C polymorphism may be a cancer susceptibility factor in Asians.
Indexed as
Identifiers
26770327PMC4694227W2258285886What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.